Finding the USP in synthetic lethality
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.
No end in sight for antibody-drug conjugate enthusiasm
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
Despite the setbacks, interest in TGF-β remains
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
Royalty Pharma comes to Adstiladrin’s rescue
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
A short-lived hold for Arcellx & Gilead
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Mirati secures an independent future
Mirati raises $300m as its chief exec departs. What’s not to like?
